Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeuroSearch has enrolled and dosed the first healthy volunteers in a clinical Phase I study with ACR343 with a view to develop this drug candidate as a new treatment for Parkinson's disease.
Subscribe to our email newsletter
The Phase I study is a randomized, double-blind and placebo-controlled single ascending dose study to evaluate the safety and tolerability as well as the pharmacokinetic profile of ACR343 after oral administration. The study will be performed in Sweden.
In preclinical studies, ACR343 has been able to stabilise motor function in a variety of models for CNS disorders. In a specific model for Parkinson’s disease, ACR343 reduces involuntary movements resulting from treatment with L-Dopa without compromising its anti-parkinsonian effects. NeuroSearch holds all rights to ACR343.
Flemming Pedersen, CEO of NeuroSearch, said: “ACR343 is the third drug candidate to be brought into the clinic as a result of our activities in the promising field of dopaminergic stabilizers, where NeuroSearch has a leading position.”